Maria R Kamstrup1, Robert Gniadecki2, Lars Iversen3, Lone Skov4, Peter Meidahl Petersen5, Annika Loft6, Lena Specht5. 1. Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: mkam0004@bbh.regionh.dk. 2. Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark. 3. Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Dermatology, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. 5. Department of Oncology and Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 6. Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Abstract
PURPOSE: Cutaneous T-cell lymphomas (CTCLs) are dominated by mycosis fungoides (MF) and Sézary syndrome (SS), and durable disease control is a therapeutic challenge. Standard total skin electron beam therapy (TSEBT) is an effective skin-directed therapy, but the possibility of retreatments is limited to 2 to 3 courses in a lifetime due to skin toxicity. This study aimed to determine the clinical effect of low-dose TSEBT in patients with MF and SS. METHODS AND MATERIALS: In an open clinical study, 21 patients with MF/SS stages IB to IV were treated with low-dose TSEBT over <2.5 weeks, receiving a total dose of 10 Gy in 10 fractions. Data from 10 of these patients were published previously but were included in the current pooled data analysis. Outcome measures were response rate, duration of response, and toxicity. RESULTS: The overall response rate was 95% with a complete cutaneous response or a very good partial response rate (<1% skin involvement with patches or plaques) documented in 57% of the patients. Median duration of overall cutaneous response was 174 days (5.8 months; range: 60-675 days). TSEBT-related acute adverse events (grade 1 or 2) were observed in 60% of patients. CONCLUSIONS: Low-dose (10-Gy) TSEBT offers a high overall response rate and is relatively safe. With this approach, reirradiation at times of relapse or progression is likely to be less toxic than standard dose TSEBT. It remains to be established whether adjuvant and combination treatments can prolong the beneficial effects of low-dose TSEBT.
PURPOSE:Cutaneous T-cell lymphomas (CTCLs) are dominated by mycosis fungoides (MF) and Sézary syndrome (SS), and durable disease control is a therapeutic challenge. Standard total skin electron beam therapy (TSEBT) is an effective skin-directed therapy, but the possibility of retreatments is limited to 2 to 3 courses in a lifetime due to skin toxicity. This study aimed to determine the clinical effect of low-dose TSEBT in patients with MF and SS. METHODS AND MATERIALS: In an open clinical study, 21 patients with MF/SS stages IB to IV were treated with low-dose TSEBT over <2.5 weeks, receiving a total dose of 10 Gy in 10 fractions. Data from 10 of these patients were published previously but were included in the current pooled data analysis. Outcome measures were response rate, duration of response, and toxicity. RESULTS: The overall response rate was 95% with a complete cutaneous response or a very good partial response rate (<1% skin involvement with patches or plaques) documented in 57% of the patients. Median duration of overall cutaneous response was 174 days (5.8 months; range: 60-675 days). TSEBT-related acute adverse events (grade 1 or 2) were observed in 60% of patients. CONCLUSIONS: Low-dose (10-Gy) TSEBT offers a high overall response rate and is relatively safe. With this approach, reirradiation at times of relapse or progression is likely to be less toxic than standard dose TSEBT. It remains to be established whether adjuvant and combination treatments can prolong the beneficial effects of low-dose TSEBT.
Authors: Ch Flores-Balcázar; D M Urías-Arce; Y Charli-Joseph; M A De León-Alfaro; S I Pérez-Álvarez; R Ramos-Prudencio Journal: Rep Pract Oncol Radiother Date: 2020-04-27
Authors: Caitlin M Brumfiel; Meera H Patel; Pranav Puri; Jake Besch-Stokes; Scott Lester; William G Rule; Nandita Khera; Jason C Sluzevich; David J DiCaudo; Nneka Comfere; N Nora Bennani; Allison C Rosenthal; Mark R Pittelkow; Aaron R Mangold Journal: Curr Treat Options Oncol Date: 2021-09-27
Authors: Matthew R Kudelka; Jeffrey M Switchenko; Mary Jo Lechowicz; Natia Esiashvili; Christopher R Flowers; Mohammad K Khan; Pamela B Allen Journal: Clin Lymphoma Myeloma Leuk Date: 2020-06-30